H
Hassane M. Zarour
Researcher at University of Pittsburgh
Publications - 118
Citations - 14897
Hassane M. Zarour is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Melanoma & Antigen. The author has an hindex of 39, co-authored 102 publications receiving 12099 citations.
Papers
More filters
Journal ArticleDOI
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid,Caroline Robert,Adil Daud,F. Stephen Hodi,Wen-Jen Hwu,Richard F. Kefford,Jedd D. Wolchok,Peter Hersey,Richard W. Joseph,Jeffrey S. Weber,Roxana S. Dronca,Tara C. Gangadhar,Amita Patnaik,Hassane M. Zarour,Anthony M. Joshua,Kevin Gergich,Jeroen Elassaiss-Schaap,Alain Algazi,Christine Mateus,Peter D. Boasberg,Paul C. Tumeh,Bartosz Chmielowski,Scot Ebbinghaus,Xiaoyun Nicole Li,S. Peter Kang,Antoni Ribas +25 more
TL;DR: In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.
Journal ArticleDOI
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
Caroline Robert,Antoni Ribas,Jedd D. Wolchok,F. Stephen Hodi,Omid Hamid,Richard F. Kefford,Richard F. Kefford,Jeffrey S. Weber,Anthony M. Joshua,Wen-Jen Hwu,Tara C. Gangadhar,Amita Patnaik,Roxana S. Dronca,Hassane M. Zarour,Richard W. Joseph,Peter D. Boasberg,Bartosz Chmielowski,Christine Mateus,Michael A. Postow,Kevin Gergich,Jeroen Elassaiss-Schaap,Xiaoyun Nicole Li,Robert Iannone,Scot Ebbinghaus,S. Peter Kang,Adil Daud +25 more
TL;DR: The results suggest that pembrolizumab at a dose of 2mg/kg or 10 mg/kg every 3 weeks might be an effective treatment in patients for whom there are few effective treatment options.
Journal ArticleDOI
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade,Zhaojun Sun,Mourad Benallaoua,Philippe Guillaume,Immanuel F. Luescher,Cindy Sander,John M. Kirkwood,Vijay K. Kuchroo,Hassane M. Zarour +8 more
TL;DR: These findings support the use of Tim-3–Tim-3L blockade together with PD-1–PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma.
Journal ArticleDOI
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas,Omid Hamid,Adil Daud,F. Stephen Hodi,Jedd D. Wolchok,Richard F. Kefford,Richard F. Kefford,Anthony M. Joshua,Amita Patnaik,Wen-Jen Hwu,Jeffrey S. Weber,Tara C. Gangadhar,Peter Hersey,Roxana S. Dronca,Richard W. Joseph,Hassane M. Zarour,Bartosz Chmielowski,Donald P. Lawrence,Alain Algazi,Naiyer A. Rizvi,Brianna Hoffner,Christine Mateus,Kevin Gergich,Jill A. Lindia,Maxine Giannotti,Xiaoyun Nicole Li,Scot Ebbinghaus,S. Peter Kang,Caroline Robert +28 more
TL;DR: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33, 12-month progression-free survival rate of 35, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%.
Journal ArticleDOI
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Omid Hamid,Caroline Robert,Caroline Robert,Adil Daud,F.S. Hodi,W. Hwu,Richard F. Kefford,Jedd D. Wolchok,Peter Hersey,Peter Hersey,Richard W. Joseph,Jeffrey S. Weber,Roxana S. Dronca,Tara C. Mitchell,Amita Patnaik,Hassane M. Zarour,Anthony M. Joshua,Qing Zhao,Erin Jensen,Sama Ahsan,Nageatte Ibrahim,Antoni Ribas +21 more
TL;DR: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolezumab in advanced melanoma.